Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130994 | 0.90 | HRH3 (0.41) | HRH3KCNH2MCHR1HTR1DHTR1B | |
| SCHEMBL4136693 | 0.88 | MCHR1 (0.41) | HRH3KCNH2MCHR1HTR1DHTR1B | |
| SCHEMBL4141039 | 0.86 | HRH3 (0.45) | HRH3KCNH2MCHR1HTR1DHTR1B | |
| SCHEMBL4136104 | 0.86 | MCHR1 (0.36) | HRH3KCNH2MCHR1HTR1DHTR1B | |
| SCHEMBL4135556 | 0.85 | CD274 (0.38) | HRH3KCNH2HTR2C | |
| SCHEMBL4135531 | 0.84 | S1PR1 (0.42) | HRH3KCNH2MCHR1ABL1 | |
| SCHEMBL4141070 | 0.84 | HTR1A (0.41) | HRH3HTR1DHTR1BOPRM1CNR2 | |
| SCHEMBL4132406 | 0.83 | MCHR1 (0.37) | HRH3KCNH2MCHR1HTR1DHTR1B | |
| SCHEMBL4140976 | 0.83 | MCHR1 (0.36) | HRH3KCNH2MCHR1 | |
| SCHEMBL4128057 | 0.83 | HRH3 (0.38) | HRH3KCNH2MCHR1HTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 657/4885MCHR1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.